Interleukin-13-vägarnas roll på smärt- och klådakänslighet hos patienter med atopisk dermatit och friska frivilliga (IL-13)
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the interleukin-13 is involved in inflammation and itch in atopic dermatitis by increasing the neuronal sensitivity to pruritogens. However, the physiological mechanisms by which IL-13 increases the itch sensitivity are unclear. The aim of this project is to use, for the first time in humans, the monoclonal antibody Lebrikizumab that inhibits IL-13 with high affinity as a novel experimental tool to modulate the IL-13 pathway and evaluate its role in the transmission and processing of itch and pain.
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Silvia Lo Vecchio
- Telefonnummer: 21397785
- E-post: slv@hst.aau.dk
Studieorter
-
-
Aalborg
-
Gistrup, Aalborg, Danmark, 9260
- Rekrytering
- Aalborg University
-
Kontakt:
- Silvia Lo Vecchio, PhD
- Telefonnummer: 21397785
- E-post: slv@hst.aau.dk
-
Kontakt:
- Botilla Markussen
- Telefonnummer: 20567502
- E-post: bam@hst.aau.dk
-
Huvudutredare:
- Silvia Lo Vecchio, PhD
-
Underutredare:
- Botilla Markussen
-
Gistrup, Aalborg, Danmark, 9260
- Aktiv, inte rekryterande
- CNAP
-
-
Denmark
-
Aalborg, Denmark, Danmark, 9260
- Har inte rekryterat ännu
- Aalborg University
-
Kontakt:
- Silvia Lo Vecchio
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Healthy men and women
- 18-60 years
Exclusion Criteria:
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other drugs
- Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
- Moles, wounds, scars, or tattoos in the area to be treated or tested
- Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
- Use of systemic and topical corticosteroids
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
- Lack of ability to cooperate
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Lebrikizumab
The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4. |
Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin. A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop. A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop. |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Superficial blood perfusion
Tidsram: Baseline
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
Baseline
|
|
Mechanically evoked itch (MEI)
Tidsram: Baseline
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
Baseline
|
|
Measuring itch by computerized Visual Analog Scale Scoring
Tidsram: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable". |
1 minute after every itch induction
|
|
Measuring pain by computerized Visual Analog Scale Scoring
Tidsram: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". |
1 minute after every itch induction
|
|
Superficial blood perfusion
Tidsram: 10 minute after every itch induction
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
10 minute after every itch induction
|
|
Wheal reaction
Tidsram: 10 minute after every itch induction
|
Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. |
10 minute after every itch induction
|
|
Average pruritis and pain numerical rating scale (NRS)
Tidsram: Baseline
|
The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. |
Baseline
|
|
Skin peak pain numerical rating scale (SPP-NRS)
Tidsram: Baseline
|
According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) |
Baseline
|
|
Peak pruritus numerical rating scale (PP-NRS)
Tidsram: Baseline
|
The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) |
Baseline
|
|
Mechanically evoked itch (MEI)
Tidsram: 10 minutes after every itch induction
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
10 minutes after every itch induction
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mechanical Pain Thresholds (MPT)
Tidsram: Baseline
|
This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
Baseline
|
|
Mechanical Pain Sensitivity (MPS)
Tidsram: Baseline
|
This test is conducted with the same pinprick set used to test the MPT. |
Baseline
|
|
Pressure Pain Thresholds (PPT)
Tidsram: Baseline
|
Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. |
Baseline
|
|
Cold Detection Thresholds (CDT)
Tidsram: Baseliene
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseliene
|
|
Warm Detection Thresholds (WDT)
Tidsram: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testingdevice |
Baseline
|
|
Cold Pain Thresholds (CPT)
Tidsram: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Heat Pain Thresholds (HPT)
Tidsram: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Tidsram: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
Samarbetspartners och utredare
Sponsor
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hudmanifestationer
- Hudsjukdomar
- Patologiska tillstånd, tecken och symtom
- Hud- och bindvävssjukdomar
- Tecken och symtom
- Klåda
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Azoler
- Biologiska faktorer
- Imidazoler
- Aminer
- Etylaminer
- Autaikoider
- Inflammationsmedlare
- Biogena monoaminer
- Biogena aminer
- Histamin
- bovine adrenal medulla 8-22
Andra studie-ID-nummer
Andra studie-ID-nummer
- N-20240029
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .